A PARP Inhibitor Keeps Some Cancers In Check For Years

By /
as seen in Forbes

Lynparza—a PARP inhibitor taken as an oral tablet, daily— keeps qualified cases of advanced ovarian cancer in check for two years, as compared to placebo.

Scroll to Top